Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

Similar articles for PubMed (Select 17328053)

1.
2.
3.

The role of modelling in prioritising and planning clinical trials.

Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P.

Health Technol Assess. 2003;7(23):iii, 1-125. Review.

4.

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden.

Willis MS.

Int J Technol Assess Health Care. 2002 Fall;18(4):791-807.

PMID:
12602080
5.

An economic approach to clinical trial design and research priority-setting.

Claxton K, Posnett J.

Health Econ. 1996 Nov-Dec;5(6):513-24.

PMID:
9003938
6.

A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach.

Ramsey SD, Blough DK, Sullivan SD.

Med Care. 2008 May;46(5):542-8. doi: 10.1097/MLR.0b013e318160b479.

PMID:
18438203
7.

Setting priorities for research.

Fleurence RL, Torgerson DJ.

Health Policy. 2004 Jul;69(1):1-10.

PMID:
15484602
8.

Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial.

Majumdar SR, Lier DA, Beaupre LA, Hanley DA, Maksymowych WP, Juby AG, Bell NR, Morrish DW.

Arch Intern Med. 2009 Jan 12;169(1):25-31. doi: 10.1001/archinte.169.1.25.

PMID:
19139320
9.

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.

Jansen JP, Gaugris S, Bergman G, Sen SS.

Curr Med Res Opin. 2008 Mar;24(3):671-84. doi: 10.1185/030079908X260998. Epub 2008 Jan 24.

PMID:
18221588
10.

Problems in interpreting cost effectiveness in clinical trials. Experimental versus implementation costs.

De Nino LA, Mulrow CD, Gerety MB, Averyt EC.

Online J Curr Clin Trials. 1993 Apr 10;Doc No 44:[4864 words; 42 paragraphs].

PMID:
8306003
11.

[The necessity of cost-effectiveness analysis in osteoporosis].

Lamy O, Krieg MA.

Rev Med Suisse. 2007 Jun 13;3(115):1521-5. French.

PMID:
17682796
12.

[Economic concepts for measuring the costs of illness of osteoporosis: an international comparison].

Viktoria Stein K, Dorner T, Lawrence K, Kunze M, Rieder A.

Wien Med Wochenschr. 2009 May;159(9-10):253-61. doi: 10.1007/s10354-009-0674-8. German.

PMID:
19484209
13.

Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Sculpher M, Fenwick E, Claxton K.

Pharmacoeconomics. 2000 May;17(5):461-77. Review.

PMID:
10977388
14.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
15.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

17.

Expected value of information and decision making in HTA.

Eckermann S, Willan AR.

Health Econ. 2007 Feb;16(2):195-209.

PMID:
16981193
18.

A normative analytic framework for development of practice guidelines for specific clinical populations.

Owens DK, Nease RF Jr.

Med Decis Making. 1997 Oct-Dec;17(4):409-26.

PMID:
9343799
19.

Value of information of a clinical prediction rule: informing the efficient use of healthcare and health research resources.

Singh S, Nosyk B, Sun H, Christenson JM, Innes G, Anis AH.

Int J Technol Assess Health Care. 2008 Winter;24(1):112-9. doi: 10.1017/S0266462307080142.

PMID:
18218176
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk